Reprint

Rheumatic Diseases: Pathophysiology, Targeted Therapy, Focus on Vascular and Pulmonary Manifestations

Edited by
April 2022
178 pages
  • ISBN978-3-0365-3641-5 (Hardback)
  • ISBN978-3-0365-3642-2 (PDF)

This book is a reprint of the Special Issue Rheumatic Diseases: Pathophysiology, Targeted Therapy, Focus on Vascular and Pulmonary Manifestations that was published in

Biology & Life Sciences
Chemistry & Materials Science
Medicine & Pharmacology
Summary

This e-book summarises the latest advances in the rheumatic diseases with a focus on the recent efforts of vascular and pulmonary manifestations and anticipate the new and future directions of these research topic. Rheumatic diseases represent a heterogeneous group of severe autoimmune disorders. The present Special Issue aims to provide an overview of the complexity of vascular and pulmonary manifestations of rheumatologic diseases and helps in knowledge to manage them. The eleven published articles here collected underline the complexity of rheumatic diseases and the difficult to treated them. The manuscripts provide an overview of the pathophysiology and current treatment regimes of these disorders, highlighting tools which assist with diagnosis, risk stratification and therapy. Finally, we underline the importance of a multidisciplinary team working using the skills of clinicians, radiologists, and pathologists.

Format
  • Hardback
License
© 2022 by the authors; CC BY-NC-ND license
Keywords
systemic sclerosis; scleroderma; interstitial lung disease; pulmonary function tests; high-resolution computed tomography; rheumatic; interstitial lung disease; pulmonary arterial hypertension; targeted therapy; systemic lupus erythematosus; airway disease; interstitial lung disease; shrinking lung syndrome; diffuse alveolar hemorrhage; pleurisy; infection; pulmonary arterial hypertension; systemic sclerosis; scleroderma; cardiopulmonary exercise testing; osteopontin; pulmonary arterial hypertension; systemic sclerosis; connective tissue diseases; systemic sclerosis; pulmonary involvement; microvascular involvement; pulmonary arterial hypertension; interstitial lung disease; nailfold capillaroscopy; rheumatoid arthritis; interstitial lung diseases; CX3CL1/fractalkine; CX3CR1; M1 macrophage; M2 macrophage; SKG mice; heart failure; 3D-echocardiography; ventricular function; outcome; systemic sclerosis; ventricular-arterial coupling; antifibrotic agents; COVID-19; interstitial lung disease; IPF; progressive fibrosing ILD; UIP; pharmacological interactions; fibromyalgia; gastrointestinal symptoms; probiotic; VSL#3®; efficacy; tolerability; polymyalgia rheumatica; vagus nerve stimulation; inflammatory response; PMR; t-vns